Xenon Pharmaceuticals Inc
XENEHealthcare|Biotechnology|Canada
$68.94
-2.05 (-2.89%)
Tangible Book
$13.85
Upcoming Data Readouts (5)
Aug 2026
Est. completion
P3Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379n=450
Oct 2026
Est. completion
P3Focal Onset Seizures
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100n=360
Apr 2027
Est. completion
P3Primary Generalized Tonic-Clonic Seizures
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142n=160
May 2027
Est. completion
P3Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407n=450
Jun 2028
Est. completion
P3Bipolar Disorder
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516n=400
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.